Stimulation of TLR7 and TLR8 with R848 (resiquimod®) led to activation of NF-kB, COX2, and BCL-2 in human NSCLC cells, thus promoting proliferation [34]. Here, TLR7 is linked to non-small cell lung carcinoma.